| 王晓辉,沙树奎,闫嘉俊,等.血管内皮生长因子及基质金属蛋白酶在喉鳞状细胞癌病人临床诊断及预后判断中的意义分析[J].安徽医药,2021,25(4):793-796. |
| 血管内皮生长因子及基质金属蛋白酶在喉鳞状细胞癌病人临床诊断及预后判断中的意义分析 |
| The value of vascular endothelial growth factor and matrix metalloproteinases in the clinical diagnosis and prognosis of patients with laryngeal squamous carcinoma |
| |
| DOI：10.3969/j.issn.1009-6469.2021.04.039 |
| 中文关键词: 喉肿瘤 血管内皮生长因子类 基质金属蛋白酶 临床分期 预后 |
| 英文关键词: Laryngeal neoplasm Vascular endothelial growth factors Metalloproteinase Clinical stage Prognosis |
| 基金项目: |
|
| 摘要点击次数: 1229 |
| 全文下载次数: 446 |
| 中文摘要: |
| 目的分析血管内皮生长因子(VEGF)及基质金属蛋白酶(MMPs)在喉鳞状细胞癌病人临床诊断及预后判断中的价值。方法以南阳市中医院耳鼻咽喉头颈外科 2010年 12月至 2015年 12月收治的 180例喉鳞状细胞癌病人为研究对象，分析不同临床分期病人 VEGF及 MMPs的表达。以医院同期健康体检者 160例为对照组。结果不同临床分期(Ⅰ期、 Ⅱ期、 Ⅲ期、 Ⅳ期)喉鳞状细胞癌病人 VEGF［(0.24±0.04)、(0.29±0.06)、(0.34±0.08)、(0.44±0.09)］、基质金属蛋白酶 2(MMP2)［(0.28±0.07)、(0.36±0.06)、(0.45±0.08)、(0.57±0.08)］、基质金属蛋白酶 9(MMP9)［(0.24±0.05)、(0.29±0.07)、(0.39±0.08)、(0.50±0.09)］和金属蛋白酶组织抑制因子 1(TIMP1)［(0.31±0.07)、(0.34±0.05)、(0.40±0.07)、(0.52±0.10)］及金属蛋白酶组织抑制因子 2(TIMP2)［(0.29±0.07)、(0.34±0.06)、(0.40±0.07)、(0.55±0.12)］蛋白表达的水平，随着喉鳞状细胞癌临床分期的增加而随之逐步升高(P<0.05)；且 VEGF、MMP2/9蛋白表达水平与喉鳞状细胞癌病人预后有明显的相关性，随着 VEGF、MMP2/9表达的增强，病人的预后逐渐变差。结论 VEGF及 MMPs表达与喉鳞状细胞癌病人临床分期密切相关，且可作为病人预后的标志物。 |
| 英文摘要: |
| Objective To explore the value of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) inthe clinical diagnosis and prognosis of patients with laryngeal squamous carcinoma.Methods A total of 180 cases of laryngeal squamous carcinoma admitted to Department of Otolaryngology, Head and Neck Surgery, Nanyang Hospital of Traditional Chinese Medicinefrom December 2010 to December 2015 were chosen for the study. The expressions of VEGF and MMPs were assayed in patients at different clinical stages. Another 160 individuals who had health checkup at the same period were taken as control.Results There were significant differences in the protein expressions of VEGF [(0.24 ± 0.04), (0.29 ± 0.06), (0.34 ± 0.08), (0.44 ± 0.09)], matrix metalloproteinase-2 (MMP2) [(0.28 ± 0.07), (0.36 ± 0.06), (0.45 ± 0.08), (0.57 ± 0.08)], MMP9 [(0.24 ± 0.05), (0.29 ± 0.07), (0.39 ± 0.08), (0.50 ±0.09)], tissue inhibitors of metalloproteinases (TIMP1) [(0.31 ± 0.07), (0.34 ± 0.05), (0.40 ± 0.07), (0.52 ± 0.10)] and TIMP2 [(0.29 ±0.05), (0.39 ± 0.08), (0.50 ± 0.09)] among patients at different clinical stages (stage I, II, III, and IV). The results showed that the expressions of serum VEGF, MMP2, MMP9, TIMP1 and TIMP2 were increased gradually with the advance of the clinical stage (P<0.05). The results also revealed that there was an evident correlation between the protein expressions of VEGF and MMP2/9 and the prognosis of the patients, and the higher the serum VEGF, MMP2, MMP9, the worse the prognosis of the patients.Conclusion Serum MMPs and VEGF are closely related to the clinical stage of patients with laryngeal squamous carcinoma and can be taken as indicators for their prognosis. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
